FDA Drug Safety Communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR)

[6-14-2016] The U.S. Food and Drug Administration (FDA) has strengthened the existing warning about the risk of acute kidney injury for the type 2 diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR).

http://www.fda.gov/Drugs/DrugSafety/ucm505860.htm

Source: FDA Center for Drug Evaluation and Research - What's New - June 14, 2016 Category: Drugs & Pharmacology Source Type: news